Our previous studies have shown that SMM-189 can be used in clinical studies to treat central nervous system diseases [49] and might serve as a unique probe in diseases like colitis to evaluate the signaling mechanisms associated with CB2 inverse agonist anti-inflammatory activity. The gene discussed is CNR2; the disease is colitis.